Biocon announced that the Board of Biocon Biologics (subsidiary of Biocon) has approved the allotment of 1,97,99,305 equity shares at face value of Rs. 10 each at an issue price of Rs. 280.31 per share including a premium of Rs. 270.31 per share to the Investor i.e. Beta Oryz, a wholly owned subsidiary of ADQ against investment of Rs 555 crore. Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.